Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04614415
Other study ID # LQ5I-19-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 14, 2020
Est. completion date December 31, 2024

Study information

Verified date October 2023
Source Fidia Farmaceutici s.p.a.
Contact Nicola Giordan
Phone +39 349 823 2111
Email ngiordan@fidiapharma.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study includes two study groups, one involves treatment with auto-cross-linked Hyaluronic acid by intralesional and hypodermic injection, repeated after two weeks (T14), while the control arm provides an equal treatment but with isotonic saline solution. Enrolled patients will be randomized into 2 groups with an allocation of 2:1 in study treatment arm and control arm respectively. They will be evaluated using the POSAS scale before the treatment and re-evaluated at 30, 90 and 180 days after treatment. The scar evaluation will be completed by an ultrasound assessment at time 0 (T0), 30 (T30), T90 and T180 and the DLQI (Dermatology Life Quality Index) to be assessed at time 0 (T0), 30 (T30), 90 (T90) and 180 (T180). In subjects that will consent, a small surgical biopsy for an explorative evaluation of the scar tissue will be performed before (T0) and after treatment (T30) for a histological assessment.


Recruitment information / eligibility

Status Recruiting
Enrollment 78
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Signed written informed consent - Male or female subjects aged = 18 and = 85 years - Subjects with hypertrophic scars caused by trauma, burn or iatrogenic injury with or without involvement of the mobile joints - Scar > 2 to < 25 cm2 of surface - Scar not previously treated with corticosteroids, laser or other invasive treatments - Scar present for at least 12 months - Scar located in all areas of the body with the exception of the face and neck - Fitzpatrick skin score of I-VI - Subjects willing to comply with all the steps of treatment and follow-up visits - Subjects willing to refrain from any cosmetic intervention in the area to be treated during the clinical investigation - Female of child-bearing potential (i.e. not in menopausal status from at least one year or permanently sterilized) must have a negative urine pregnancy test prior the first treatment Exclusion Criteria: Subjects with type I and type II diabetes mellitus - Subjects with oncological diseases in progress or in remission - Subjects receiving immunosuppressive drugs and corticosteroids, anticoagulants, antiplatelet agents - Subjects with autoimmune diseases including connectivitis - Subjects with congenital or acquired immunodeficiencies (including metabolic ones) - Subjects with known allergy or hypersensitivity to hyaluronic acid or its derivatives - Participation in clinical trials/investigations in the last 30 days - Pregnant or breastfeeding women - If female and of child-bearing potential, subject not using a highly effective method of birth control and not willing to use it during the participation to the clinical investigation - Subjects not willing to avoid tanning during the clinical investigation - Subjects with inflammations of the skin, including rosacea - Subject with skin infection in the area to be treated - Subjects having a high probability of non-compliance with the study procedures according to Investigator's judgement

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Autocrosslinked Hyaluronic aid
IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
Other:
placebo
The placebo consists in an isotonic saline solution (NaCl 0.9%)

Locations

Country Name City State
Italy AOU Ospedali Riuniti- SOD Chirurgia ricostruttiva e chirurgia della mano Ancona
Italy U.O. Centro Grandi Ustionati Ospedale Bufalini di Cesena - AUSL Cesena
Italy U.O.C. Chirurgia Plastica e Centro Ustioni Azienda Ospedaliero-Universitaria di Parma Parma
Italy U.O.C. Centro Ustioni Azienda Ospedaliero-Universitaria Pisana Pisa

Sponsors (1)

Lead Sponsor Collaborator
Fidia Farmaceutici s.p.a.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to Day 90 in POSAS total score for Observer The performance of two injections of IAL-SYSTEM ACP in improving the quality of the scar after 90 days from the first treatment in patients with hypertrophic scars will be evaluated by the mean change from baseline to Day 90 in POSAS total score for Observer. 90 days after treatment
Secondary To evaluate the performance of IAL-SYSTEM ACP in improving the quality of the scar Change from baseline to post-baseline visits (T30, T90 and T180) in total POSAS scores (sum total of Patient and Observer scores), and POSAS total score for Patient and Observer after 30 and 180 days from the first treatment
Secondary To assess the changing in the Quality of life after 30, 90 and 180 days from the first treatment with the Dermatology Life Quality Index (DLQI) Change from baseline to post-baseline visits (T30, T90 and T180) in DLQI score (dermatology quality of life Index) after 30, 90 and 180 days from the first treatment
Secondary To assess the changing in the dermal volume after 30, 90 and 180 days from the first treatment Change from baseline to post-baseline visits (T30, T90 and T180) in dermal volume measured by ultrasound after 30, 90 and 180 days
Secondary Safety of the treatment. Number of patients with treatment related adverse events Safety evaluation examining the local and systemic adverse effects as consequence of the treatment and any other adverse event occurred during the study. throug clinical investigation completion, an average one year
See also
  Status Clinical Trial Phase
Completed NCT03376620 - Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients Phase 3
Terminated NCT03935594 - Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars Phase 2
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Recruiting NCT06033430 - Effectiveness of Dry Needling in Linear Scar Tissue N/A
Recruiting NCT03631368 - Treatment of Hypertrophic Scars With Intradermal Botox Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Recruiting NCT02168634 - The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial N/A
Completed NCT02030275 - A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults Phase 2
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Completed NCT04643223 - Effect of Elastic Bandage With Tension on the Inflammatory Response of Hypertrophic Scars N/A
Completed NCT03986346 - The Vascularity Changes of Scars With Laser Therapy N/A
Completed NCT04619589 - Characterization of Dyschromic Hypertrophic Scar
Completed NCT05412745 - Class I Medical Device on Post-surgical Scars N/A
Completed NCT06347081 - Effect of Nd-YAG Laser on Hypertrophic Scar N/A
Terminated NCT03403621 - Hypertrophic Scar Prevention by Novel Topical Gel Application Phase 1/Phase 2
Completed NCT00754247 - A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Phase 4
Recruiting NCT03692273 - Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar N/A
Completed NCT03795116 - Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention Phase 2
Not yet recruiting NCT03850119 - Nanofat on Wound Healing and Scar Formation N/A